secwatch.observer — SEC 8-K summary
======================================

Issuer:     FMC CORP (FMC)
CIK:        0000037785
Form:       8-K
Filed at:   2026-07-29T20:44:06+00:00
Accession:  0000037785-26-000139
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FMC Q2 revenue down 17% to $867M, GAAP loss $1.49/share; lowers full-year guidance
--------------------------------------------------------------------------------

- Q2 revenue $867M (-17% YoY); GAAP net loss $187M ($1.49 loss per share); adjusted EPS $0.26 (-62%).
- Adjusted EBITDA $153M (-26% YoY); cash from ops $363M including $200M rimisoxafen licensing payment.
- Full-year 2026 outlook lowered: revenue ex-India $3.50B-$3.70B, Adj. EBITDA $620M-$680M, Adj. EPS $1.19-$1.49.
- Strategic actions: India sale ($252M), rimisoxafen licensing ($200M), Newark sale-leaseback ($114M), Tessenderlo equity ($400M) – ~$1B for debt reduction.
- Board concludes strategic review; Q3 Adj. EBITDA guided $120M-$140M, Q4 $275M-$315M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/37785/000003778526000139/0000037785-26-000139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/37785/000003778526000139/fmc-20260729.htm
  HTML page:      https://secwatch.observer/filing/0000037785-26-000139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer